EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Webinar on the use of platform technologies in the non-clinical and clinical domains - agenda

2 March 2026, 9:30 – 12:15 (CET/CEST)
Virtual meeting/ EMA, Amsterdam

The proposal for the EU pharmaceutical legislation introduces the concepts of platform technologies and platform marketing authorisation.
The European Medicines Agency organises a webinar bringing together regulators and medicine developers to discuss the use of platform technologies beyond the quality and manufacturing domains. We invite interested parties to share insights and case studies on the use of non-clinical and clinical platform technologies and platform marketing authorisation (ITFsecretariat@ema.europa.eu).
The main objectives of the webinar are:

- Clarifying how the current EU legal framework allows for the development and marketing of individualised therapies (n=1) and for the use of prior knowledge in Marketing Authorisation dossiers;
- Presenting case studies on the use of platform technologies in the non-clinical and clinical domains and exploring their possible applications and values;
- Discussing the challenges and identify opportunities related to the use of platform approaches;
- Facilitating the implementation of the NPL provisions on platform technologies and platform marketing authorisation.

Webinar on the use of platform technologies in the non-clinical and clinical domains - agenda

Co-chairs: Falk Ehmann (EMA) and Oriane Blanquie (EMA)

Monday 2 March 2026, 09:30 – 12:15 (CET/CEST)

09:00	**Joining and technical checks**	
09:25	**Welcome and opening speech**	
	Steffen Thirstrup (EMA)	**5 min**
09:30	**Session 1: Leveraging platform approaches in the development of therapies in the EU**	
	Current regulatory routes for individualised therapies *Ilona Reischl (AGES, CAT chair)*	**15 min**
	Regulatory experience on the use of prior knowledge and platform approaches *Ragini Shivji (EMA) and Javier Pozo Gonzalez (EMA)*	**15 min**
	Provisions of the new EU Pharmaceutical Legislation on platform approaches *Florian Schmidt (European Commission)*	**15 min**
	Q&A session	**15 min**
10:30	**Coffee break**	
10:40	**Session 2: Non-clinical and clinical case studies**	
	Utilisation and Acceptability of platform technologies: results from a multistakeholder survey *Stephanie Oskam (CBG-MEB), Marjon Pasmooij (CBG-MEB)*	**15 min**
	Case 1 (academia) *Annemieke M Aartsma-Rus (University of Leiden)*	**15 min**
	Case 2 (large pharma) *Mihai Bilanin (EFPIA)*	**15 min**

Case 3 (SMEs) **15 min**
Alexander Natz (Eucope)

11:40 Session 3: Panel discussion

All + Thomas Girard (EMA) **30 min**

12:10 Closing remarks

Wrap up **5 min**
Falk Ehmann (EMA)